Dompé Farmaceutici S.p.a

This Phase 2 trial tested whether adding reparixin, an anti-inflammatory drug, to standard care could improve lung function in adults with moderate to severe acute respiratory distress syndrome (ARDS). The study enrolled 66 patients on mechanical ventilators. Researchers measured…

This study followed 24 people with stage 1 neurotrophic keratitis, a rare eye condition that can damage the cornea, who had previously used OXERVATE eye drops in an earlier study. Researchers checked if the cornea stayed healed up to 30 months after treatment. The goal was to see…

This study tested an eye drop called OXERVATE in 37 adults with stage 1 neurotrophic keratitis, a condition where the cornea loses feeling and doesn't heal properly. The treatment was given for 8 weeks, and patients were followed for 24 weeks to see if the cornea healed safely. T…

This phase 2 trial tested two strengths of rhNGF eye drops against a placebo in 317 adults with moderate-to-severe dry eye disease. Participants used the drops three times a day for 4 weeks, followed by 4 weeks of monitoring. The goal was to see if the drops could improve dry eye…

This Phase 3 study tested cenegermin (Oxervate) eye drops against a placebo in 85 adults with severe dry eye caused by Sjogren's syndrome, who were already using cyclosporine drops. The goal was to see if cenegermin could increase tear production and reduce eye discomfort over 4 …